Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1314 in Moderate-to-Severe Plaque Psoriasis (Phase II)
CTR20191914Phase 2Terminated
- Sponsor
- Hengrui Therapeutics
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of vunakizumab in plaque psoriasis, sponsored by Hengrui Therapeutics. Started Oct 2019; status: terminated.
02
Drugs
vunakizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20191914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191914.